UNSPSC 51372324: Ocfentanil hydrochloride

This classification denotes an opioid receptor agonist with the molecular formula C22H27FN2O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z8T88FVW9V, chemically known as acetamide, n-(2-fluorophenyl)-2-methoxy-n-(1-(2-phenylethyl)-4-piperidinyl)- but more generally known as ocfentanil hydrochloride, which bears US NIH Compound Identifier 60575. Most nations, for tariff and trade purposes, schedule ocfentanil hydrochloride under HS 29333999 and SITC 51574.

As of Q4 2014, OCFENTANIL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Ocfentanil hydrochloride bears US NLM identifiers UMLS ID C2698645 and NCI Concept Code C76850. SMILES: COCC(=O)N(C1CCCCC1F)C2CCN(CC2)CCC3CCCCC3.CL.

UNSPSC 51372324 Ocfentanil hydrochloride is a Commodity code that covers the procurement of specific pharmaceutical active ingredients and finished pharmaceutical products by state and local health agencies, primarily through cooperative purchasing vehicles and competitive solicitations. Recent activity shows state and local governments buying naloxone and drug deactivation systems, generic multi-source pharmaceuticals through cooperative agreements, and exploring direct-to-manufacturer prescription programs to manage pharmacy benefit costs and improve community health outcomes. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance administering purchases for participating state and local facilities across multiple jurisdictions including Oregon).

Recent opportunities span Florida, Texas, and Minnesota. Seminole County, Florida released IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, due July 26, 2023. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for implementing a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program that would establish direct relationships between the state's pharmacy benefit program and pharmaceutical manufacturers. The Minnesota Department of Administration's Office of State Procurement, administering the MMCAP cooperative purchasing alliance, issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products with a March 26, 2026, response deadline, requiring vendor compliance with FDA requirements, cGMP, and the Drug Supply Chain Security Act, with distribution through three authorized wholesalers and awards effective July 1, 2026.